IUC26688-95

Abstract Code: IUC26688-95   S100A9 Identifies Distinct Circulating Myeloid Cell Subsets in Metastatic Prostate Cancer Iglesias 1, M.F. Guerra 2, R. Hinojosa Altamirano 3, M. Beckel 4, A. Bruke 5, E. Sandes 6, M.N. Gandur Quiroga 7, Y. Langle 8 (1) Universidad de...

IUC26679-95

Abstract Code: IUC26679-95   A pilot study of the implementation of the G8 frailty assessment in oncology clinics for patients with newly diagnosed metastatic hormone sensitive prostate cancer Hague 1, S. Appleyard 2, A. Balagopal 2, N. Samkaoui 2 (1) East Sussex...

IUC26675-91

Abstract Code: IUC26675-91   Patterns of de novo metastatic prostate cancer presentation: clinical, biological, and topographic characteristics at Mohammed VI University Hospital Bondjeke Nkumindamu 1, L. Afani 1, O. Zouiten 1, M. El Fadli 1, R. Belbaraka 1 (1)...

IUC26673-89

Abstract Code: IUC26673-89   Reducing adverse outcomes following local anaesthetic trans-perineal prostate biopsies Moshtael 1, M. Johnston 1, G. Crowther 1, J. Brewin 1 (1) Department of Urology, Salisbury NHS Foundation Trust, BSW Hospitals Group, Salisbury, UK...

IUC26669-94

Abstract Code: IUC26669-94   The LDR BURST Trial: A Randomised Comparison of Toxicity Outcomes following LDR Brachytherapy vs 5-Fraction SBRT with a Rectal Spacer for Localised Prostate Cancer Hayhurst 1, S. Uribe-Lewis 2, J. Uribe 2, C. Mikropoulos 2, S. Otter...

IUC26667-92

Abstract Code: IUC26667-92   Assessment of QRISK®3 and Major Cardiovascular Events in Patients with Metastatic Hormone-Sensitive Prostate Cancer Treated with ADT ± ARPI ± Docetaxel: A Retrospective Cohort Study Alom 1, A. Kutty 1, G. Neola 1, L. Pedapati 1, A....
error: Content is protected !!